The FDA has approved GE Healthcare?s Cysview (hexaminolevulinate hydrochloride) for the detection of nonmuscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.
The FDA has approved GE Healthcare’s Cysview (hexaminolevulinate hydrochloride) for the detection of nonmuscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.
The optical imaging agent is used with the Karl Storz (Tuttlingen, Germany) D-Light C Photodynamic Diagnostic system to perform cystoscopy with the blue light setting as an adjunct to the white light setting.
"Data from the pivotal 305 trial demonstrates that Cysview cystoscopy significantly improves detection of papillary bladder cancer, leading to more complete resection of bladder cancer and significantly improving disease-free survival when compared to white light cystoscopy," said lead investigator H. Barton Grossman, MD, of M.D. Anderson Cancer Center, Houston. "We found this to be true both for patients with initial and recurrent disease."
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.